Parabilis Medicines, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Parabilis Medicines announced strong Q2 2026 results, highlighting advancements in zolucatetide trials, a major collaboration with Regeneron, and a robust cash position extending runway to 2030.